Corkill M M, Jobanputra P, Gibson T, Macfarlane D G
Rheumatology Unit, Guy's Hospital, London.
Br J Rheumatol. 1990 Feb;29(1):41-5. doi: 10.1093/rheumatology/29.1.41.
Sixty-two patients with long established but symptomatic ankylosing spondylitis were treated with sulphasalazine or matching placebo in a randomized double-blind controlled trial for 48 weeks. There were no consistent significant differences between the treatment groups in clinical parameters despite multiple assessments. Equivalent numbers in each group were able to decrease or stop non-steroidal anti-inflammatory drug ingestion during the study period (four active, eight placebo). Side effects were reported more commonly in the sulphasalazine group (27 versus 17, NS), but only 21 patients stopped treatment because of side effects (12 versus 9, NS). Analysis of the subgroup with an initial ESR greater than 20 mm/h failed to show any persisting differences of response between sulphasalazine and placebo. We conclude that sulphasalazine therapy does not have a role in the treatment of chronic ankylosing spondylitis.
在一项随机双盲对照试验中，62例患有长期确诊且有症状的强直性脊柱炎患者接受了柳氮磺胺吡啶或匹配的安慰剂治疗，为期48周。尽管进行了多次评估，但治疗组之间在临床参数上没有一致的显著差异。在研究期间，每组中能够减少或停止服用非甾体抗炎药的人数相当（4例服用活性药物，8例服用安慰剂）。柳氮磺胺吡啶组报告的副作用更常见（27例对17例，无统计学意义），但只有21例患者因副作用停止治疗（12例对9例，无统计学意义）。对初始血沉大于20mm/h的亚组分析未显示柳氮磺胺吡啶和安慰剂之间在反应上有任何持续差异。我们得出结论，柳氮磺胺吡啶疗法在慢性强直性脊柱炎的治疗中不起作用。
